Zogenix, Inc. Announces Clinical Study Results for sumatriptan DosePro™, a Novel Migraine Treatment
SAN DIEGO--(BUSINESS WIRE)--Zogenix, Inc. (“Zogenix”), a private, specialty pharmaceutical company, today announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.